NPM1 and acute myeloid leukemia: Furthermore, high PD-L1 expression has recently been documented in NPM1-mutated AML cells, especially in leukemic progenitor/stem cell compartments, suggesting that NPM1-mutated AML patients may potentially be candidates for immune checkpoint PD-1/PD-L1-driven immunotherapy [34].